CAJ | 학술논문

目的：探讨灯盏花素联合罗氟司特治疗慢性阻塞性肺疾病（ COPD ）的临床疗效及对患者免疫功能的影响。方法116例COPD患者随机分为对照组58例和试验组58例。对照组给予抗感染、吸氧及止咳化痰平喘等常规治疗。试验组在对照组的基础上静脉滴注灯盏花素40 mg，每天1次；口服罗氟司特500μg· d－1。2组疗程均为2周。观察比较2组临床疗效、肺功能、细胞免疫功能及不良反应发生情况。结果试验组的治疗总有效率为94.8％，显著高于对照组的81.0％（ P＜0.05）。治疗后，2组患者第1秒用力呼气容积（ FEV1）和第1秒用力呼气容积／用力肺活量（ FEV1／FVC ）均显著升高。试验组的 FEV1为（2.66±0.40）L，FEV1／FVC 为（72.03±8.18）％，均显著高于对照组 FEV1（1.92±0.37）L，FEV1／FVC（59.41±7.09）％（均P＜0.05）。治疗后，对照组T淋巴细胞亚群CD4＋、CD4＋／CD8＋均显著高于对照组， CD8＋显著低于对照组（均P＜0.05）。治疗过程中，2组均未出现严重不良反应。结论灯盏花素联合罗氟司特是COPD的有效治疗方案，可以显著提高临床疗效，改善肺功能，并增强患者的细胞免疫功能，且不良反应轻微。
목적：탐토등잔화소연합라불사특치료만성조새성폐질병（ COPD ）적림상료효급대환자면역공능적영향。방법116례COPD환자수궤분위대조조58례화시험조58례。대조조급여항감염、흡양급지해화담평천등상규치료。시험조재대조조적기출상정맥적주등잔화소40 mg，매천1차；구복라불사특500μg· d－1。2조료정균위2주。관찰비교2조림상료효、폐공능、세포면역공능급불량반응발생정황。결과시험조적치료총유효솔위94.8％，현저고우대조조적81.0％（ P＜0.05）。치료후，2조환자제1초용력호기용적（ FEV1）화제1초용력호기용적／용력폐활량（ FEV1／FVC ）균현저승고。시험조적 FEV1위（2.66±0.40）L，FEV1／FVC 위（72.03±8.18）％，균현저고우대조조 FEV1（1.92±0.37）L，FEV1／FVC（59.41±7.09）％（균P＜0.05）。치료후，대조조T림파세포아군CD4＋、CD4＋／CD8＋균현저고우대조조， CD8＋현저저우대조조（균P＜0.05）。치료과정중，2조균미출현엄중불량반응。결론등잔화소연합라불사특시COPD적유효치료방안，가이현저제고림상료효，개선폐공능，병증강환자적세포면역공능，차불량반응경미。
Objective To investigate the clinical effect of breviscapine in combination with roflumilast in the treatment of chronic obstructive pulmonary disease ( COPD ) and its effects on immunological function.Methods A total of 116 patients with COPD were randomly divided into two groups , each was 58 cases.Control group was treated with regular treatment.Experiment group was treated with breviscapine 40 mg, qd in combination with roflumilast 500 μg · d -1.After two weeks treatment , the clinical efficacy , pulmonary function , cellular immune function and adverse reactions were observed.Results The total efficiency of experiment group was 94.8%, significantly higher than that of 81.0%in control group ( P <0.05 ) . The FEV1 and FEV1/FVC were (2.66 ±0.40)L and ( 72.03 ± 8.18 )% in experiment group, statistically higher than ( 1.92 ±0.37 ) L and ( 59.41 ±7.09 )% in control group ( P <0.05 ).Levels of CD4 + and CD4 +/CD8 + were statistically higher than that in control group , and level of CD8 + was statistically lower than that in control group after treatment ( P<0.05 ).No severe adverse reaction was happened in both groups during the treatment.Conclusion Breviscapine and roflumilast were effective in the treatment of COPD , which can significantly increase clinical efficacy , improve pulmonary function and cellular immune function with slight adverse reactions.